 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12345678910111213...4748» |
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal: Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study. (Pubmed Central) - Apr 26, 2024
This study first reported that anlotinib combined with Stupp regimen is a safe and feasible regimen for newly diagnosed patients with H3K27M-DMG. Further, anlotinib showed significant efficacy for H3K27M-DMG located in the infratentorial region.
- | New P2 trial, Metastases: RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer (clinicaltrials.gov) - Apr 25, 2024
P2, N=32, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, PD(L)-1 Biomarker, IO biomarker: Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway. (Pubmed Central) - Apr 25, 2024
Anlotinib effectively inhibits proliferation and induces apoptosis in MCL both in vitro and in vivo. This inhibition is likely linked to suppressing phosphorylation in the PI3K/Akt/mTOR pathway.
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical efficacy and safety of mTOR inhibitor in patients with advanced unresectable epithelioid hemangioendothelioma (EHE). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6798;
At present, there is no standard treatment for EHE, we can roughly see the efficacy of mTOR inhibitor everolimus in some EHE patients, mainly disease stability. Emphasis on side effect management, improve tolerance, and systematic treatment of EHE needs to be further explored.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A phase II trial of anlotinib combined chemotherapy as second-line and above therapy in HER2-negative advanced breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6775;
Anlotinib combined with chemotherapy showed a promising efficacy with an acceptable safety profile for second-line and above patients with HER2-negative metastatic breast cancer. Further studies enrolling more patients are still needed.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus everolimus as first-line treatment for advanced non () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6764;
P2
We will report more data in the future. Clinical trial information: NCT05124431.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6752;
The addition of anlotinib to first-line immunotherapy in combination with chemotherapy results in extended PFS and OS in patients with ES-SCLC without additional AEs. The preliminary results warrant further investigation of this treatment modality in ES-SCLC.
- Evaluating progression-free survival of EGFR exon 20ins in patients with advanced non-small lung cancer receiving EGFR inhibitors: A real-world data study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6748;
Our exploratory analysis suggested improved PFS among female, and younger patients. No differences were observed by treatment line or treatment.
- Imfinzi (durvalumab) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6746;
P2
Durvalumab plus anlotinib and chemotherapy demonstrated promising PFS, ORR and manageable safety profile for the first-line treatment of ES-SCLC. Clinical trial information: NCT04660097.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Gemcitabine and cisplatin chemotherapy plus penpulimab combined with or without anlotinib as neoadjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A prospective, phase II clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6676;
P2
This finding requires validation in longer follow-up and larger phase III clinical trials. Clinical trial information: NCT05193617.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Meta-analysis of the efficacy and safety of anlotinib combined with chemotherapy in the treatment of small cell lung cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6639;
The findings in the present study suggest that the combination of anlotinib with CT could provide improved PFS, ORR, DCR, and OS in patients with SCLC. This meta-analysis may innovate new prospects in the therapy for SCLC.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
PD-(L)1 inhibitors plus anlotinib: A superior option for second-line treatment of extensive-stage small cell lung cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6621;
This meta-analysis may innovate new prospects in the therapy for SCLC. PD-(L)1 inhibitors plus anlotinib and/or chemotherapy has promising efficacy and manageable toxicity as second-line therpay of ES-SCLC.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
Preliminary data of a phase Ib/II trial evaluating the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular carcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6542;
P1/2
Enrollment in the phase II trial is ongoing and updated clinical data will be presented. Clinical trial information: NCT05924997.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Systematic therapy for metastatic solid pseudopapillary neoplasm of the pancreas: A single-center experience. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6536;
Metastatic SPN of the pancreas may be not chemosensitive. Targeted therapy, such as anlotinib and everolimus, appears to be a potential therapeutic option.
- Kaitanni (cadonilimab) / Akesobio
The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study in China. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6379;
In this heavily treated advanced NSCLC patient cohort, cadonilimab-based regimens only showed moderate anti-tumor efficacy with a generally tolerable and manageable safety profile. More evidence supporting administration of cadonilimab is needed in NSCLC patients refractory to previous anti-PD-1/PD-L1 therapy.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6309;
Camrelizumab with chemotherapy followed by maintenance camrelizumab plus apatinib showed preliminary efficacy and acceptable safety profile, and might be a promising regimen as first-line treatment in ES-SCLC. Clinical trial information: ChiCTR2000035599.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A phase II trial of anlotinib and fulvestrant in patients with HR-positive and HER2-negative, secondary aromatase inhibitor () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6215;
P2
Further results are expected. Clinical trial information: NCT05075512.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6175;
P=N/A
When combined with chemotherapy or immunotherapy, it can improve PFS and OS without significantly increasing toxicity. In particular, it shows promising intracranial ORR and PFS in patients with brain metastases.
- AiTan (rivoceranib) / HLB Bio Group
Efficacy and safety of apatinib combined with nab-paclitaxel for second-line treatment of metastatic triple negative breast cancer (TNBC): An open-label phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6121;
P1/2
The combination of apatinib and nab-paclitaxel showed promising antitumor activity in patients with metastatic TNBC as a second-line treatment, with a manageable safety profile. Clinical trial information: NCT05019690.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
The effects of anlotinib combined with chemotherapy following progression on cyclin-dependent kinase 4/6 inhibitor in hormone receptor-positive metastatic breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6116;
Clinical trial information: NCT05019690. The study preliminarily demonstrates that anlotinib combined with chemotherapy may be an optional recommendation for patients with HR+/HER2- metastatic breast cancer who have progressed after CDK4/6i.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Sintilimab and anlotinib combination therapy in PD-L1-positive recurrent/metastatic cervical carcinoma: A 3-year follow-up of ALTER-C201 study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5953;
PIK3CA and KMT2C may serve as potential prognostic biomarkers, but further studies are needed to validate their effectiveness. Patients who experience progression after treatment with the sintilimab plus anlotinib may still benefit from treatment with chemotherapy or combination therapy of other immune checkpoint inhibitors.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Predictive value of C reactive protein (CRP) and D-dimer in patients with advanced cervical cancer treated with sintilimab and anlotinib. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5950;
CRP and D-dimer predict survival in advanced cervical cancer patients undergoing combined ICI/ VEGF-TKI therapy. We advocate further work to validate utilisation of CRP and D-dimer as prognostic biomarkers for advanced cervical cancer in clinical practice.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Single-cell sequencing to elucidate the disparities in the immune microenvironment between PIK3CA mutants and wild types. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5949;
We advocate further work to validate utilisation of CRP and D-dimer as prognostic biomarkers for advanced cervical cancer in clinical practice. Nevertheless, in our preceding study entitled 'Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5921;
P2
The preliminary results demonstrated that anlotinib plus penpulimab as a first-line therapy for persistent, recurrent, or metastatic cervical cancer showed promising antitumor efficacy and manageable safety profile. Clinical trial information: NCT05028504.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
The clinical application of circulating tumor cells (CTCs) for immunotherapy in advanced pancreatic cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5535;
These results suggest that PD-L1+ CTCs might be used as a predictor of the efficacy of cancer immunotherapy in advanced PDAC, and provide a new monitoring method for the precise treatment of advanced PDAC. The expanding sample size test is now ongoing.
- AiTan (rivoceranib) / HLB Bio Group
Alterations of the tumor microenvironment (TME) in recurrent glioblastoma following apatinib in combination with temozolomide. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5484;
P=N/A
Our study suggests that the combination of apatinib and TMZ may potentially provide clinical benefits in treating rGBM by modulating genes associated with cell proliferation, promoting apoptosis, regulating hypoxia, and enhancing immune response within the tumor microenvironment. Clinical trial information: NCT04814329.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Safety and efficacy of camrelizumab and apatinib in combination with IMRT in unresectable hepatocellular carcinoma: A non-randomised phase 2 study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5457;
These findings warrant to be confirmed in phase 3 prospective studies. Clinical trial information: ChiCTR2000035052.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with apatinib as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A phase 2 trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5456;
P2
The study enrollment is ongoing, and further survival and safety data will be reported in the future. Clinical trial information: NCT03917966.
- Benlysta (belimumab) / GSK, AiTan (rivoceranib) / HLB Bio Group
The safety and efficacy of adebelimumab combined apatinib and hepatic artery infusion chemotherapy in the treatment of unresectable hepatocellular carcinoma: A retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5427;
Background: The combination of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) used for hepatic arterial infusion chemotherapy (HAIC) has shown promise for advanced hepatocellular carcinoma (HCC) patients. The combination of Adebelimumab, apatinib, and FOLFOX-HAIC demonstrated manageable safety and encouraging results for unresectable HCC.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A pilot study early result. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5403;
P2
These data suggest Tislelizumab + Anlotinib+Chemo may be a promising novel treatment option for patients with pancreatic cancer. Clinical trial information: NCT05681390.
- AiTan (rivoceranib) / HLB Bio Group
Effect of AFPGC immune-microenvironment and resistance to immunotherapy. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5398;
P2
AFPGC is resistant to PD-1 monoclonal antibody. Combined treatment with SB265610 or apatinib can alleviate or reverse the resistance, making it the most promising treatment regimen for AFPGC.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5353;
P2
Furthermore, these conclusions required to be confirmed in subsequent trials. Clinical trial information: NCT05038813.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5331;
The combination of anlotinib plus penpulimab and nab-paclitaxel as first-line therapy for advanced ESCC demonstrated promising efficacy and manageable safety profile. And the conclusions needed to be confirmed in subsequent trials.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Update results of anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5327;
P2
The conclusion should be validated in more patients consecutively. Clinical trial information: NCT05812430.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Updated data from a prospective, phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5324;
More ESCC pts would be recruited in the future. Clinical trial information: ChiCTR2200064848.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5319;
P2
The combination of TQB2450 plus anlotinib, paclitaxel and cisplatin, demonstrated encouraging efficacy and manageable toxicity in patients with advanced ESCC when used as first-line treatment. Clinical trial information: NCT05013697.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5307;
P2
Anlotinib plus chemotherapy as first-line treatment has shown promising efficacy and acceptable safety and maybe a favorable option for advanced LMs GI tumors, especially for pancreatic cancer. Clinical trial information: NCT05262335.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Real-world study of anlotinib monotherapy and combination therapy for unresectable hepatocellular carcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5300;
Clinical trial information: NCT05262335. Anlotinib demonstrated satisfactory efficacy and safety as a single agent and in combination with other therapies in the treatment of uHCC, with potential benefit on health-related quality of life.
- Stivarga (regorafenib) / Bayer
Efficacy and safety of regorafenib plus ICIs as second-line treatment in advanced HCC post-frontline treatment failure: A real-world study from a single center. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5294;
8% of patients, sorafenib plus ICIs in three patients, apatinib plus ICIs, donafenib plus ICIs, and bevacizumab plus ICIs each in one patient... Regorafenib with ICIs is a promising and tolerable second-line treatment for advanced HCC after initial therapy failure.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5281;
Standard chemotherapy was Cohort B: mFOLFOX or irinotecan plus capecitabine... The retrospective analysis suggests that the triple regimen as second-line treatment for advanced BTC pts may help improve the efficacy and survival, and is worthy of further prospective exploration.
- Comparison of checkpoint inhibitor () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5277;
Among ICI combinations, better survival and response rates were reported with sintilimab + bevacizumab, atezolizumab + bevacizumab, and camrelizumab + rivoceranib. Therefore, these regimens should be preferred for treatment of advanced HCC as first line therapy in patients who can tolerate these regimens.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5267;
Anlotinib plus PD-1 blockades demonstrated encouraging efficacy and tolerable adverse reactions among patients with advanced ESCC who had received immunotherapy previously and the feasibility of PD-1 blockades rechallenge in ESCC was promising to be elucidated. Clinical trial information: ChiCTR2300070777.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in unresectable hepatocellular carcinoma (uHCC): Subgroup analysis of patients treated with camrelizumab (cam) + rivoceranib (rivo) in the CARES-310 trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5264;
P3
Clinical trial information: NCT03764293. >aP value is calculated based on log-rank test; bORR defined as CR+PR per RECIST v1.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
An open-label, placebo-controlled, randomized phase II trial of camrelizumab combined with or without apatinib or capecitabine in the treatment of previously treated advanced pancreatic cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5227;
These analyses revealed combined immunotherapy could be used as a new option for posterior line treatment in previously treated metastatic PDAC. Clinical trial information: ChiCTR1900024095.
- Sulanda (surufatinib) / Hutchmed, Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety of second-line treatment with surufatinib for anlotinib-resistant radioiodine-refractory differentiated thyroid cancer: An exploratory multicenter study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4756;
In patients with anlotinib-resistant RR-DTC, second-line surufatinib treatment yielded promising efficacy and tolerable toxicity, warranting randomized controlled studies on RR-DTC refractory to first-line targeted therapy. Clinical trial information: ChiCTR2100052020.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Multi-omics study on the molecular mechanism of anlotinib in regulating tumor metabolism. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4728;
Clinical trial information: ChiCTR2100052020. This study provides potential metabolic biomarkers for anlotinib treatment in tumors, and may identify potential biomarkers and pathways associated with the therapeutic efficacy of anlotinib treatment.
- AiTan (rivoceranib) / HLB Bio Group, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Precision oncology and AI: The ACMA system for personalized treatment matching using real-world data. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4548;
It customizes the interplay of these features with medical logic, delivering tailored outputs through the LLM. This approach offers an economical, convenient, and timely solution, setting a new benchmark in personalized oncology and establishing ACMA as a leader in the field.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial. (Hall A; Poster Bd #: 167a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3923;
P3
Secondary endpoints were progression-free survival, objective response rate per RECIST 1.1 and mRECIST, disease control rate per RECIST 1.1 and mRECIST, time to progression, duration of response, time to response, and safety. Whole-Exome Sequencing and RNA Sequencing of tumor biopsy samples were performed for predictive biomarker exploration.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial. (Hall A; Poster Bd #: 166b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3922;
P2, P3
Allowing a dropout rate of 15%, we aimed to enroll 192 patients. The trial is currently screening eligible patients.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study. (Hall A; Poster Bd #: 115) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3865;
P2
PAAG regimen as first-line treatment was demonstrated to be tolerable, with promising anti-tumor activity in mPC. The identified biomolecular markers revealed potential to guide precision treatment of PAAG for mPC.